Cancer Treatment: Patient Travel Times

Debate between Jackie Doyle-Price and Tim Farron

Wednesday 10th January 2018 Westminster Hall

[The Parliamentary Under-Secretary of State for Health (Jackie Doyle-Price)]

It is a pleasure to serve under your chairmanship, Sir Christopher. It is also a pleasure to respond to the hon. Member for Westmorland and Lonsdale (Tim Farron). I wish to associate myself with his opening comments in praise of the NHS. Demand for NHS services is constantly increasing. We always want the best we can possible get, but by making that case, we often sound as if we are talking the NHS down. Nothing could be further from the truth—we have the best national health service in the world. I am glad to see that the hon. Gentleman is nodding his head, and I am grateful for the persuasive way in which he made his case. He can consider that a very good representation in response to the consultation to which he referred. The points he has made will be reflected on keenly.

Improving cancer outcomes remains a priority for the Government. The work under way is making a difference: cancer survival rates in England have never been higher and have increased year-on-year since 2010. The decrease in cancer deaths means that around 7,000 people are alive today who would not have been had things stayed the same.

We are committed to implementing every one of the 96 recommendations in the cancer strategy for England and to making a difference to the millions of people living with the disease and the thousands more diagnosed each year. We are providing the funding to match our commitment. NHS England has confirmed £607 million in funding to support the delivery of the strategy between 2017-18 and 2020-21.

We want our cancer services to be the best in the world, and we want patients to have access to the treatment and services that will give them the best chance of a successful clinical outcome. That includes the time they spend travelling for treatment. We know that cancer treatments can be arduous. Patients often undergo treatment daily and treatments can last several weeks at a time. Ideally, we want patients to have treatments at their local hospital.

However, specialised cancer treatments are not always best delivered locally. We want patients to have the best possible care available, but for certain cancers that sometimes means seeing a specialist multidisciplinary team with a full range of clinical expertise and capability. Although local is good, we clearly cannot always have specialist care provided as locally as we would like.

A perfect example of that is proton beam therapy treatment. Patients with high-priority cancer types requiring that treatment are sent to Florida and Switzerland at great cost to the NHS, because we have been unable to provide it here. In April 2012, the Government announced a £250 million investment to build proton beam therapy treatment facilities at the Christie in Manchester and University College London Hospitals. The Christie’s facilities will become operational later this year and will offer patients access to world-class treatment on the NHS.

Over the last few years, we have seen astounding technological advances. The UK is leading from the front in using cutting-edge technology in the form of whole genome sequencing to transform healthcare and health research. Wherever possible, it is right that patients have easy access to those life-saving treatments.

The same principle applies to radiotherapy. Around four in 10 of all NHS cancer patients are treated using radiotherapy. Recent advances have helped to target radiation doses at cancer cells more precisely, which means far fewer doses, better outcomes and improved quality of life for patients. That is a crucial part of why survival rates have continuously risen in England.

One of the cancer strategy’s key objectives is to deliver a modern, high-quality cancer service. In October 2016, NHS England announced a £130 million fund to modernise radiotherapy across England that will upgrade or replace older treatment devices over two years.

[Tim Farron]

The hon. Lady mentioned proton beam therapy, which is a wonderful treatment. We are grateful for the investment of more than one Government, which has ensured that it is coming to Manchester and London. She also talked about upgrading existing equipment, which is a reminder that 80% of commonly occurring cancers will still be treated by linear accelerators, albeit regularly upgraded. Therefore the delivery of proton beam therapy and other specialist and precise treatments, and the investment in more locally delivered treatment from linear accelerators in places such as Westmorland, are not mutually exclusive. We need to do both.

[Jackie Doyle-Price]

I absolutely agree—the two are complementary and need to be key ingredients in a successful strategy to combat cancer.

NHS England is not only modernising existing radiotherapy services; it is currently consulting on a new model for them, as the hon. Gentleman said. The aim is to encourage radiotherapy providers to work together in networks to concentrate expertise and improve pathways for patients requiring radical radiotherapy for less common cancers. That will help to improve access to more innovative radiotherapy treatments, increase clinical trial recruitment and ensure that radiotherapy equipment is fully utilised. There is no intention to reduce the number of radiotherapy providers, nor is that considered to be a likely outcome of the proposals being consulted on.

We will continue to ensure that travel times are taken into consideration when looking at cancer treatment in this country. The National Cancer Registration and Analysis Service is evaluating the impact on cancer outcomes of patients living different distances from a cancer centre. Public Health England is also testing travel times from several available datasets, so a programme of work can be established that incorporates data on travel times.

One of the first outputs of that work will be a report on whether there is any demonstrable difference in radiotherapy treatments associated with the time taken to travel to a specialist cancer centre. We expect the first results of that work to be published in the spring. I am sure the hon. Gentleman will have a considerable interest in the outcome.

In the current NHS England consultation, there are proposals that would allow local commissioners and providers to plan, review and redesign services through a joint radiotherapy board. Any case for change would determine the optimum location to achieve the best impact for patients, so it would be possible for patients requiring radiotherapy for common cancers to be treated at a satellite centre. Specialised commissioners will always want to balance patient travel with issues such as the sustainability of the service, whether the service is accessible enough to patients to be financially viable, and ensuring that patients who have to travel are supported in other ways, including through transport and accommodation.

I hope that meets with a positive reaction from the hon. Gentleman. We are consulting on making services more accessible and looking at travel times. I dare say that we will continue to have this debate over the coming months, not least because of his private Member’s Bill.

I understand that the hon. Gentleman recently met his local clinical commissioning group at Morecambe Bay to discuss the accessibility of services. I am encouraged that that dialogue is taking place at a local level.

I hope that what I have set out gives the hon. Gentleman some reassurance. I emphasise that cancer remains a priority for the Government. We remain committed to ensuring the best possible treatment and to achieving easy access in terms of travelling time for all cancer patients, regardless of where they live. I am grateful to the hon. Gentleman for securing this debate.

Question put and agreed to.